ArticleCancer cell international2026
NUDT1 drives osteosarcoma progression and serves as a robust predictor of clinical outcomes.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Osteosarcoma (OS) is a primary bone malignancy characterized by high metastatic potential and poor prognosis. Nudix hydrolase 1 (NUDT1) plays a key role in preventing oxidative DNA damage, yet its functional significance in OS remains to be fully defined. By integrating transcriptomic data from the TARGET, GEO, and an independent cohort from our institution, we found that NUDT1 is significantly upregulated in OS tissues and cell lines. High NUDT1 expression serves as an independent predictor of unfavorable overall survival. Functional assays demonstrated that NUDT1 promotes OS cell proliferation, migration, and invasion in vitro and accelerates tumor growth in vivo. Mechanistically, GSEA indicated that NUDT1 is associated with metabolic pathways including glycolysis and glutathione metabolism. We confirmed that NUDT1 maintains OS cell fitness by restraining ROS accumulation and limiting oxidative DNA damage, effects that were partially reversed by the antioxidant N-acetyl-L-cysteine (NAC). Furthermore, NUDT1 expression levels were found to correlate with the tumor immune microenvironment, specifically showing associations with the infiltration levels of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.